These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39253078)

  • 1. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.
    Peng Z; Gao J; Huang L; He Y; Tang H; Zong S; Pei Y; Pei F; Ge J; Liu X; Yue L; Zhou J; Li X; Yue D; Chen Y; Chen C; Wu X; Feng X; Li C
    Front Immunol; 2024; 15():1426640. PubMed ID: 39253078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
    Yabe M; Ohtsuka Y; Watanabe K; Inagaki J; Yoshida N; Sakashita K; Kakuda H; Yabe H; Kurosawa H; Kudo K; Manabe A;
    Int J Hematol; 2015 Feb; 101(2):184-90. PubMed ID: 25504334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
    Ai Y; Lu X; Zhu T; Zhu Y; Liu H; Sun S
    Medicine (Baltimore); 2020 Dec; 99(50):e23606. PubMed ID: 33327329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group.
    Stieglitz E; Ward AF; Gerbing RB; Alonzo TA; Arceci RJ; Liu YL; Emanuel PD; Widemann BC; Cheng JW; Jayaprakash N; Balis FM; Castleberry RP; Bunin NJ; Loh ML; Cooper TM
    Pediatr Blood Cancer; 2015 Apr; 62(4):629-36. PubMed ID: 25704135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
    Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
    Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.
    Auberger J; Clausen J; Willenbacher W; Erdel M; Gunsilius E; Petzer A; Gastl G; Nachbaur D
    Int J Hematol; 2008 May; 87(4):382-386. PubMed ID: 18418698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
    Yoshida N; Sakaguchi H; Yabe M; Hasegawa D; Hama A; Hasegawa D; Kato M; Noguchi M; Terui K; Takahashi Y; Cho Y; Sato M; Koh K; Kakuda H; Shimada H; Hashii Y; Sato A; Kato K; Atsuta Y; Watanabe K;
    Biol Blood Marrow Transplant; 2020 May; 26(5):902-910. PubMed ID: 31790827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
    Dvorak CC; Satwani P; Stieglitz E; Cairo MS; Dang H; Pei Q; Gao Y; Wall D; Mazor T; Olshen AB; Parker JS; Kahwash S; Hirsch B; Raimondi S; Patel N; Skeens M; Cooper T; Mehta PA; Grupp SA; Loh ML
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27034. PubMed ID: 29528181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human leukocyte antigen disparities reduce relapse after hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: A single-center retrospective study from China.
    Lin YC; Luo CJ; Miao Y; Wang JM; Luo CY; Qin X; Cai JY; Li BS; Chen J
    Pediatr Transplant; 2021 Mar; 25(2):e13825. PubMed ID: 33131184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China.
    Cai Y; Zhang J; Yi M; Zhang W; Liu X; Zhang X; Wan Y; Chang L; Zhang L; Chen X; Guo Y; Zou Y; Chen Y; Li J; Zhang Y; Yang W; Zhu X
    Int J Hematol; 2023 Jan; 117(1):121-127. PubMed ID: 36182987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine.
    Wajid M A; Gupta AK; Das G; Sahoo D; Meena JP; Seth R
    Pediatr Hematol Oncol; 2020 Oct; 37(7):573-581. PubMed ID: 32459546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
    Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
    D'Angelo CR; Hall A; Woo KM; Kim K; Longo W; Hematti P; Callander N; Kenkre VP; Mattison R; Juckett M
    Leuk Res; 2020 Sep; 96():106419. PubMed ID: 32683127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
    Yang T; Lin Q; Ren J; Chen P; Yuan X; Luo X; Liu T; Zheng J; Zheng Z; Zheng X; Chen X; Zhang L; Zheng H; Chen Z; Hua X; Le S; Li J; Chen Z; Hu J
    Oncotarget; 2016 Nov; 7(48):78773-78786. PubMed ID: 27705929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic leukemia.
    Patel SA; Coulter DW; Grovas AC; Gordon BG; Harper JL; Warkentin PI; Wisecarver JL; Sanger WG; Coccia PF
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):491-4. PubMed ID: 24322499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
    Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation.
    Zhu J; Wang Q; Ren H; Dong Y; Yin Y; Wang Q; Liang Z; Liu W; Wang Q; Wang B; Li Y
    Front Immunol; 2023; 14():1274492. PubMed ID: 37928518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center.
    Gao J; Hu Y; Gao L; Xiao P; Lu J; Hu S
    BMC Pediatr; 2022 May; 22(1):312. PubMed ID: 35624441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.